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Abstract
Background—Acute decompensated heart failure (ADHF) is a leading cause of hospitalization
in older persons in the United States. Reduced physical function and frailty are major determinants
of adverse outcomes in older patients with hospitalized ADHF. However, these are not addressed
by current heart failure (HF) management strategies and there has been little study of exercise
training in older, frail HF patients with recent ADHF.
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Hypothesis—Targeting physical frailty with a multi-domain structured physical rehabilitation
intervention will improve physical function and reduce adverse outcomes among older patients
experiencing a HF hospitalization.
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Study Design—Rehabilitation Therapy in Older Acute Heart Failure Patients (REHAB-HF) is a
multi-center clinical trial in which 360 patients ≥ 60 years hospitalized with ADHF will be
randomized either to a novel 12-week multi-domain physical rehabilitation intervention or to
attention control. The goal of the intervention is to improve balance, mobility, strength and
endurance utilizing reproducible, targeted exercises administered by a multi-disciplinary team with
specific milestones for progression. The primary study aim is to assess the efficacy of the
REHAB-HF intervention on physical function measured by total Short Physical Performance
Battery score. The secondary outcome is 6-month all-cause rehospitalization. Additional outcome
measures include quality of life and costs.

Author Manuscript

Conclusions—REHAB-HF is the first randomized trial of a physical function intervention in
older patients with hospitalized ADHF designed to determine if addressing deficits in balance,
mobility, strength and endurance improves physical function and reduces rehospitalizations. It will
address key evidence gaps concerning the role of physical rehabilitation in the care of older
patients, those with ADHF, frailty, and multiple comorbidities.
Keywords
Heart Failure; Physical rehabilitation; Frailty; Hospitalization

Introduction

Author Manuscript

Acute decompensated heart failure (ADHF) is a leading cause of hospitalization in older
persons in the United States.1 Hospitalized ADHF is associated with severely reduced
health-related quality of life (QOL), persistently high rehospitalization rates,2 markedly
increased mortality,3 and costs over $16 billion per year in the United States.4 Despite
advances in the treatment of chronic heart failure with reduced ejection fraction (HFrEF),
there has been relatively little progress with respect to ADHF therapies. Current heart failure
(HF) management guidelines, even when perfectly adhered to, have had only modest impact
on ADHF outcomes, particularly rehospitalizations in the older population.2, 5 Furthermore,
several recent trials of new interventions to improve ADHF outcomes, such as remote
monitoring,6, 7 alternative diuretic regimens,8 novel pharmacologic agents9, 10 and
biomarker guidance11 have not proven beneficial. The typical older ADHF patient has >5
comorbidities that contribute to adverse outcomes.5, 12–14 Frequent non-cardiac
comorbidities may explain the unexpected finding from multiple studies that >50% of
rehospitalizations in older ADHF patients are due to non-cardiac events rather than recurrent
ADHF.3, 5, 12, 15

Author Manuscript

Multiple lines of evidence suggest that severely reduced physical function and frailty are
major determinants of adverse outcomes in older patients with hospitalized ADHF.16 We
and others have shown that even when stable with compensated cardiovascular function,
older patients with chronic HF have severe impairments in physical function due to the
combined effects of aging, cardiovascular dysfunction, and impaired skeletal muscle
function.17–19 As patients with chronic HF transition to ADHF, physical function worsens
both because of HF decompensation and accelerated physical deconditioning.20, 21 This is
further exacerbated by the hospital processes, including bed rest which can markedly
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exacerbate physical dysfunction and acute muscle loss,20, 22, 23 contributing to what has now
been termed the ‘post-hospital syndrome’.24
After resolution of the acute HF symptoms and congestion, older ADHF patients continue to
have marked impairments in physical function, including deficits in strength, balance,
mobility and endurance, and most patients meet formal definitions of frailty.20, 25
Furthermore, these deficits persist and some patients never recover baseline
function.24, 26, 27 This occurs during the most vulnerable, high risk period for
rehospitalization and adverse outcomes, up to 6 months post discharge,3 and likely
contribute to the high costs of rehospitalizations. These costs are now targeted by the
Centers for Medicare & Medicaid Services (CMS) penalties reducing payments to hospitals
with excess readmissions.28

Author Manuscript
Author Manuscript

Prior clinical trials of exercise training in HF (n>40), including those used to support the
decision by CMS to expand cardiac rehabilitation coverage to HFrEF, were restricted to HF
patients with chronic, stable disease.29–31 The largest of these, the NIH-funded HF-ACTION
trial, excluded patients with ADHF and those within 6 weeks of hospital discharge.29 This
prompted CMS to explicitly exclude recently hospitalized HF patients from cardiac
rehabilitation coverage28 and an expert consensus recommendation for a period of stability
of at least a month before enrolling HF patients in cardiac rehabilitation.32 HF-ACTION also
enrolled relatively few older patients, particularly those with multiple comorbidities,33 who
may be at increased risk for complications during cardiac rehabilitation.34 As noted above,
physical impairments in older, frail patients with ADHF are broader, including deficits in
balance and mobility, and far more severe than those observed in patients with chronic stable
HF.20 Such deficits are not typically targeted by conventional, endurance-based cardiac
rehabilitation.29 Addressing deficits in balance, mobility and functional strength may be
important for preventing early injuries in frail, older ADHF patients and for enhancing gains
in function.35, 36
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We hypothesize that targeting physical frailty among older patients experiencing a HF
hospitalization with a multi-domain structured physical rehabilitation intervention will
improve physical function and reduce adverse outcomes. The current group of investigators
completed a pilot study which showed that in older patients with ADHF, a structured
intervention targeting physical function can improve the Short Physical Performance Battery
(SPPB) score, a strong predictor of hospitalization, disability, and death.37 Based on these
findings, the National Institute of Aging funded the Rehabilitation Therapy in Older Acute
Heart Failure Patients (REHAB-HF) Trial to evaluate the efficacy of a novel, tailored,
progressive, multi-domain, 12-week physical function intervention initiated during an
ADHF hospitalization to improve physical function, as measured by SPPB (primary
outcome), and reduce all-cause rehospitalization during the 6 months after initiation of the
intervention.38
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Methods
Study Population
The REHAB-HF Trial has a target enrollment of 360 HF patients admitted for worsening
heart failure (HF), based on at least one symptom of HF and at least two signs of HF and a
change in medical treatment specifically targeting ADHF (Table 1). There is no left
ventricular ejection fraction (EF) criterion. Patients must be at least 60 years of age or
greater, performing basic activities of daily living prior to admission, able to walk at least 4
meters at the time of enrollment (assistive device allowed) and expected to be discharged to
home.

Author Manuscript
Author Manuscript

Patients are excluded if their HF is end-stage, defined as requiring or anticipating heart
transplant or left ventricular assist device within the next 6 months or expected discharge on
continuous intravenous ionotropic therapy. Patients with HF in the presence of severe
primary valvular disease, such as severe aortic stenosis or mitral regurgitation, are excluded.
Patients with advanced renal dysfunction who are currently requiring dialysis or at high risk
for progressing to dialysis during the course of the study (defined as estimated glomerular
filtration rate of < 20 mL/min/1.73 m2) are excluded due to concerns regarding ability to
adhere to the study intervention. Similarly, patients are not enrolled if they have clinically
evident dementia or significant impairment from a stroke, injury or other medical disorder
that precludes participation in the intervention or following study protocol. Potential
participants found to have mild cognitive impairment, common in older patients hospitalized
with HF,20, 39 are eligible for enrollment provided there is adequate social support for
adherence. Participants undergo screening for potential barriers to adherence using a
standardized tool to assess personal commitment to adhering to the study requirements;
degree of support from family members, caregivers and outpatient physicians; and potential
transportation barriers. Those unable or unwilling to fully commit to all aspects of study
participation or who lack support are considered high risk for non-adherence and are
excluded from the study.
Eligible patients who provide informed consent and complete baseline testing successfully
(Table 2) are randomized to attention control or to the multi-domain rehabilitation
intervention. Block randomization is employed and stratified on clinical center and EF
category (<45, ≥45). All sites use the same allocation process housed in the Coordinating
Center (Wake Forest) database (REDCap) to ensure uniform randomization.

Author Manuscript

The REHAB-HF trial is being conducted in accordance with the Declaration of Helsinki and
has been approved by Institutional Review Boards of all participating institutions. All study
participants provide informed written consent. The REHAB-HF trial is registered with
Clinicaltrials.gov (NCT02196038).
Attention Control
The usual care arm of REHAB-HF is defined as attention control due to increased
surveillance of these participants in an effort to reduce the potential bias created from
increased interactions of intervention participants with study personnel. Participants in the
attention control group will receive at least bi-weekly contact from study personnel (nurses
Am Heart J. Author manuscript; available in PMC 2018 March 01.
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or exercise physiologists) by phone or by specified study visits (weeks 4 and 12) during the
first 3 months following the index hospitalization. Information regarding symptoms, HF
transitional management program use, medical compliance, activity level, rehabilitation
received, medical resource utilization, QOL and clinical events will be collected at each of
these encounters. Participants in the attention control arm will not receive any specific
rehabilitation recommendations or exercise prescription from study personnel. Adherence to
medication regimens and follow-up appointments is encouraged.

Author Manuscript

Participants in both arms receive standard therapies as directed by their clinical providers,
which may include any of the following services: inpatient physical therapy, outpatient
physical therapy, or cardiac rehabilitation 6 weeks after discharge. All aspects of disease
management, including medical therapy and HF management, are left to the discretion of the
participant’s treating physician and are specifically not addressed by the study protocol for
either study arm. Clinical concerns raised by the participant and/or identified by study
personnel are referred to the participant’s health care provider(s) for further management.
REHAB-HF Intervention
The multi-domain rehabilitation intervention for this study is a novel integration of
rehabilitation therapies developed specifically for older HF patients who have been
hospitalized for ADHF. The goal of the intervention is to improve balance, mobility, strength
and endurance utilizing reproducible, targeted exercises administered by a multi-disciplinary
team with specific milestones for progression. The intervention is limited to physical
rehabilitation and specifically does not address other aspects of disease management or
frailty.

Author Manuscript

Frequency and Duration—The majority of the study interventions are facility-based in
the outpatient setting. These 3 times per week sessions are initiated as soon as possible
following hospital discharge, last approximately 60 minutes, and continue for 12 weeks or
36 sessions. For participants with especially low functional performance, a limited number
of these sessions may be conducted at home early following discharge (weeks 1–2). When
feasible, daily sessions of approximately 30 minutes are conducted in the hospital prior to
discharge.

Author Manuscript

Intensity—Exercise intensity is based upon patient-reported rate of perceived exertion
(RPE) using a 6–20 point scale. During the first two weeks, target intensity is low (RPE ≤
12). In the outpatient setting, target RPE is gradually increased to 13 (“somewhat hard”)
(range of 11–15) for endurance training and 15–16 for strength rehabilitation, as this level of
intensity may be necessary to obtain significant functional improvement in strength.40 After
4 weeks of the endurance intervention, intensity within the target RPE range can be adjusted
to ensure a heart rate response of ≥20 beats per minute above the resting heart rate. This is
typically needed to achieve >60% of exercise reserve capacity41 and is intended to ensure an
adequate training effect to minimize non-responders while maintaining safety.29, 42, 43
Mode—Each session includes a warm-up, one-on-one targeted rehabilitation training in
each domain (balance, mobility, strength and endurance), and a cool-down. At the beginning
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of the intervention, participants undergo standardized stratification of functional
performance in each of four domains: balance, strength, endurance and mobility (Table 3).
We anticipate a range of initial performance levels based on the REHAB-HF pilot study,
where 40% of participants were initially at the lowest level of functioning (level 1) for most
domains, 33% were at level 2, and 27% were at level 3.20 Exercises specifically targeted to
the participant’s functional level in each domain are then selected from the intervention
protocols (see Table 4 for examples).

Author Manuscript

The relative time spent on each domain during the rehabilitation session is also tailored to
the participant’s physical impairments (Figure). For example, a participant with poor
balance and functional mobility spends a greater proportion of time performing exercises
focused in these areas. Alternatively, a participant with only modest impairments in balance
and functional mobility spends most of the exercise session performing endurance and
strengthening exercises.
Progression—Progression is a key aspect of the study intervention. Participants are
continually challenged to improve physical function by advancing through a structured,
gradual progression using specific small increments in each exercise. Progression is based
on performance during one-on-one training sessions and standardized re-assessment of
functional performance in each domain conducted every 2 weeks (Table 3 and 4).

Author Manuscript

Safety—Pre-specified safety protocols based on vital signs and reported symptoms will be
followed. Should a participant report a significant change in health status before or during
exercise that presents a safety risk for continued exercise participation, a study physician
onsite or the participant’s primary doctor will be consulted prior to exercise participation.
Vital signs, including heart rate, blood pressure and pulse oximetery will be recorded at the
beginning and conclusion of each session. Routine assessment of heart rate and RPE during
the exercise session will also be used to enhance exercise safety. Exercising blood pressure
and pulse oximetery will be monitored on a symptom-driven basis. Telemetry monitoring is
not performed.

Author Manuscript

Intervention fidelity—Several strategies are used to promote consistent implementation
of the intervention. These include: 1) a standardized protocol with a) specific rehabilitation
exercises for each of the 4 domains; b) selection of initial exercises and progression based on
standardized assessments (Table 3); c) detailed progression in small increments for each
exercise; 2) training comprised of a) full day of in-person training of the study
interventionists (experienced exercise physiologists and physical therapists) prior to study
launch, including protocol review, demonstration videos using patient volunteers and handson practice sessions; b) interactive study-wide webinars conducted at least annually; 3)
continued monitoring to identify and address challenges related to fidelity. This includes
tracking of exercises performed during each intervention session through a study-wide
database. These reports are reviewed and discussed during bi-weekly teleconferences of
study leadership for each participant actively engaged in the study physical rehabilitation
intervention. The intervention supervisor at each site also reviews the implementation of the
study intervention for each participant with the treating interventionist, addressing any
challenges that arise.
Am Heart J. Author manuscript; available in PMC 2018 March 01.
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Home exercise—All participants randomized to the study intervention receive one home
evaluation by study personnel following hospital discharge lasting approximately 30–45
minutes. The purpose of the home visit is to identify areas for safe performance of the home
exercise prescription. Participants are instructed in low-intensity walking at their usual pace,
gradually increasing toward a goal of 30 minutes daily. Functional strengthening exercises
(e.g. sit-to-stand from chair, step-ups, if feasible, and calf raises) are incorporated and
customized based on patient goals and identified deficits. This brief home exercise program
is to be performed on non-program days at least twice per week. Whenever possible, study
personnel attempt to engage the participant’s caregivers/family to support home exercise.

Author Manuscript

Maintenance—Following the completion of the outpatient intervention, an individualized
maintenance exercise prescription is developed by the interventionist based on the
participant’s performance at the end of the 12-week supervised training intervention.
Participants in the intervention arm will receive phone calls at months 4, 5, and 6, to discuss
adherence to the exercise prescription and to gather information regarding study endpoints
(Table 2). Physical activity is also monitored by accelerometers worn by participants in both
study arms. These accelerometers are for monitoring only and do not have a display visible
to the participant.
Retention and Adherence

Author Manuscript

Retaining participants with a high disease burden in a study that involves a significant
commitment is expected to be challenging. The study addresses retention prior to enrollment
by carefully explaining the commitment, identifying and addressing potential barriers,
particularly if a participant is randomized to the intervention arm, and having the participant
sign a behavioral agreement that details the requirements of the study. Adherence screening
confirming participant commitment and support by family or caregivers and personal
physicians is conducted prior to randomization. Participants unable to fully commit during
this screening will not be randomized. Once randomized, the study will provide a clear
schedule of all visits, reminders, same-day phone calls for any missed visits, involvement of
family and caregivers, and sharing of test results and intervention progress, if applicable.
Transportation support will also be available.
Interruptions to the study intervention, including illness and hospitalization, are anticipated.
To help ensure each participant has a reasonable opportunity to complete the study
intervention and that the physical performance outcome measures reflect the intended
intervention of this study, limited extensions (2–4 weeks) are included in the study protocol
for participants in both study arms.

Author Manuscript

Our primary measure of adherence is the percent of prescribed sessions attended. We will be
able to assess this and other aspects of exercise adherence through tracking of sessions
attended, sessions missed, reasons for missed sessions, as well as exercise performed in each
session attended.
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The primary aim of the study is to assess the efficacy of the REHAB-HF intervention on
physical function measured by the change in total SPPB score from baseline to 3 months.
This and other study measures are obtained by independent, trained assessors who are
blinded to participant’s intervention allocation. The SPPB measures physical function using
3 components: usual gait speed over 4 meters, time to complete 5 chair rises, and standing
balance with progressively narrow base of support. Each component is scored on a 0–4 scale
and summed for an overall score range of 0–12.44 The SPPB was chosen as the primary
outcome because it is a well-accepted, standardized, reliable, validated measure of physical
function in the older population that can be collected safely and easily in clinic, home, and
hospital settings, including in older patients hospitalized with ADHF.20, 25 The overall SPPB
score and components are highly predictive of important clinical outcomes, including
disability, hospitalization, nursing home admission, and death.44–46 The SPPB is sensitive to
change in health status47 and responsive to exercise training.48–50 Interventions that improve
SPPB also improve clinical events.48 A clinically meaningful but small change in SPPB
score is 0.5 units and a substantial change is 1.0 units.50

Author Manuscript

Six-month all-cause rehospitalization was chosen as the key secondary outcome because: it
is the most frequent adverse outcome in ADHF; it is associated with impaired physical
function, reduced quality of life, increased mortality, and increased cost; and our pilot data
and others’ suggest that it is responsive to physical function interventions.37 A
rehospitalization is defined as a hospital stay >24 hours, including prolonged emergency
department visits or observational unit stays, for any cause. For exploratory analyses and
safety monitoring, rehospitalizations will be categorized by the site investigators as primarily
due to non-cardiovascular, HF, or other cardiovascular (myocardial infarction, acute
coronary syndrome without myocardial infarction, arrhythmia, peripheral vascular) cause,
and whether they were related to the study intervention or assessments.
Additional exploratory analyses will examine the effect of the intervention on: the
components of the SPPB; 6-minute walk distance; QOL (both HF-specific and global);
frailty phenotype as originally described by Fried;51, 52 depression; cognitive function; allcause combined rehospitalization and death; global rank endpoint of SPPB score, all-cause
rehospitalization and death; HF-specific rehospitalizations; cardiovascular events;
rehospitalization days; facility-free days; deaths; falls; and biomarkers. Sub-group analyses
based on EF category (<45, ≥45) are also planned.
Statistical Analysis and Sample Size

Author Manuscript

The effect of the intervention on SPPB score measured 3 months post-randomization will be
estimated and tested for significance using analysis of covariance, where the randomized
arm is the between-subject grouping variable and the pre-randomized measure of SPPB
score, clinical site, age, gender, and EF category (<45, ≥45) will be covariates. Least square
means will be used to estimate the intervention effect. Tests will be conducted at the 5%
two-sided level of significance.
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The secondary aim of the study is to assess the intervention’s effect on the total number of
all-cause rehospitalizations during the 6 months following discharge from the index
hospitalization. Since the count of all-cause rehospitalizations per participant may not be
normally distributed, the effect of the intervention on total all-cause rehospitalizations will
be estimated using a Poisson model for modeling count data, where the randomized arm is
the between-subject grouping variable and clinical site, age, gender, and EF category will be
covariates. A supplemental analysis will be performed adding the duration of the index
hospitalization and the number of inpatient intervention sessions as additional covariates. To
account for the expected dropouts or non-compliance with the intervention, we will
incorporate compliance (“on treatment”) as collected by adherence measurements. Simple
observational treatment comparisons that include only patients who complied with specified
levels of the intervention protocol will be examined as supportive information, recognizing
the limitations of such comparisons.
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The REHAB-HF pilot study showed an estimated intervention effect of an increase of 1.13
units in 3-month SPPB score (the primary outcome) or a 17.9% relative increase above the
least square mean for the attention control group, with a mean square error from the analysis
of covariance model of 3.269.37 This study is designed to have 80% power to detect a 10%
treatment difference (0.63 absolute difference) in the 3-month least square mean of SPPB
score. Based on the findings of the REHAB-HF pilot study, this requires 258 evaluable
participants. Assuming an 85% retention rate, the study requires randomizing 304
participants (25.3 per site per year).

Author Manuscript

In the completed pilot study, the number of all-cause rehospitalizations within 6 months was
reduced 29.3% by the intervention (1.673±0.392 per patient in the attention control group
vs. 1.157±0.349 in the intervention group). We performed additional work with an analysis
of a contemporaneous sample of 239 consecutive patients aged ≥ 65 years admitted with the
primary diagnosis of ADHF. This confirmatory sample yielded a 6-month rehospitalization
event rate estimate within 0.5% of our attention control group, giving confidence in our pilot
study estimate. This study is designed to have 80% power to detect a 25% reduction (0.41
absolute difference) in the total number of all-cause rehospitalizations during the 6 months
following the index hospitalization. This requires 334 participants; assuming loss to followup of 5%, the study requires randomizing 352 total participants. Rounding up, this study will
randomize a total of 360 patients, providing > 80% power for the primary and secondary
aims.
Economic analysis
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Patient-level information on medical resource use, patient time spent on rehabilitationrelated activities and QOL, as measured with the EuroQol 5-Dimension 5-Level
(EQ-5D-5L), is collected throughout the 6-month follow-up period (Table 2).
Interventionists and support staff will provide supplemental information to estimate costs to
provide the rehabilitation intervention. These data will be used to estimate direct medical
costs, non-direct medical costs, indirect (patient time) costs and quality-adjusted survival.
Mean costs and quality-adjusted survival over the six-month follow-up period in the
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REHAB-HF will be compared between patients randomized to the rehabilitation
intervention versus attention control.
If the intervention does not produce a net cost-savings in the short-term, a long-term costeffectiveness analysis will be performed to assess the incremental costs of the intervention
versus the incremental impact of the intervention on quality-adjusted survival. The
previously-developed and validated TEAM-HF Cost-Effectiveness Model53 will be used to
generate longer-term estimates of costs, survival and quality-adjusted survival. The
economic evaluation of the REHAB-HF intervention will be used to propose payment
models for third-party payers (e.g. CMS) and accountable care organizations and health
maintenance organizations who provide care to HF patients on a capitated basis.

Support
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The REHAB-HF trial is supported by NIH grant R01AG045551. Additional sources of
support for this research and manuscript development include NIH grants R01AG18915 and
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REHAB-HF is a multicenter, prospective randomized controlled trial designed to determine
if a tailored, structured, progressive multi-domain physical rehabilitation intervention
addressing deficits in balance, mobility, strength, and endurance, improves physical function
and reduces rehospitalizations compared to attention control in older patients hospitalized
with ADHF. This is the first HF clinical trial to employ a multi-domain physical
rehabilitation intervention beginning during ADHF hospitalization and transitioning to the
outpatient setting. REHAB-HF is designed to address multiple high-priority gaps in the
evidence regarding exercise training in HF patients, including those with markedly reduced
physical function who are unable to undertake traditional exercise training, > 60 years, with
multiple co-morbidities, who are women, and who have HF with preserved EF
(HFpEF).37, 54, 55 The trial has consistently met enrollment targets with 160 of 360
participants enrolled to date and study completion anticipated in 2019.
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We have incorporated several novel features into our study design to meet the specific needs
of older, frail recently hospitalized HF patients that distinguishes REHAB-HF from
prior29, 30 and ongoing56–58 investigations of exercise training in HF. During our pilot study,
we observed unexpectedly severe impairments in all functional domains, including balance
and mobility.20 Prior studies have shown that not identifying and correcting balance
impairments early during rehabilitation can lead to increased injuries.36 In response to this
and in an effort to maximize training response while minimizing the risk of injuries and
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falls, we provide one-on-one training to deliver an individually tailored, multi-domain
intervention with an early emphasis on addressing deficits in balance, mobility and
functional strength.34, 59 Progressively more endurance training is incorporated as balance,
mobility and strength improve (Figure). The timing of the REHAB-HF intervention is also
unique in that it is initiated as early as the time of hospitalization following initial
stabilization of ADHF. The study intervention is also highly adaptable to a wide range of
functional impairments while promoting gradual, structured progression and maintaining
fidelity.
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We hypothesize that the widespread, severe functional impairments targeted by our
intervention are largely due to skeletal muscle dysfunction as a result of the systemic effects
of the HF clinical syndrome, medical comorbidities, aging, acute illness and hospital-related
immobility.16, 55 Given the systemic nature of these mechanisms, we expect the intervention
will have similar efficacy in older frail patients recovering from ADHF regardless of EF.
This is supported by several observations. Older patients with chronic HFpEF and HFrEF
have similar functional impairments with similar underlying skeletal muscle abnormalities,
including shift in fiber types, reduced capillary density, and impaired mitochondrial
function.17, 60–63 During ADHF, patients with both types of HF are subject to acute muscle
loss and dysfunction associated with hospitalization and immobility.64–67 In our pilot, the
nature and severity of functional impairments in older patients with ADHF were
independent of EF.20 The similarities in functional impairments and their proposed
mechanisms may also help explain the remarkably similar vulnerability to adverse clinical
outcomes, frequently due to non-cardiac causes, observed in older patients following a HF
hospitalization across the spectrum of EF.3 In fact, many of the proposed contributing factors
to functional impairments and clinical outcomes, such as aging, comorbidities and acute
immobility, are common to a broader population of older, frail hospitalized patients at risk
for the “post-hospital syndrome”,24 supporting the potential further generalizability of study
findings.
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While the focus of the study is on addressing physical function impairments, descriptors of
impairments common in acutely ill, older patients (e.g. frailty, falls, cognition, urinary
incontinence) will also be captured. Such syndromes are by nature non-disease specific and
are not typically targeted by HF management strategies. However, they may be associated
with HF, worsened as components of the post-hospital syndrome,24 can complicate HF
management and contribute to adverse clinical outcomes in older patients with HF. The
frequency and severity of these geriatric syndromes will be tracked over the course of the
study, and the contribution to QOL, economic and clinical outcomes during the high risk
period following ADHF hospitalization will be assessed. Such insights could help inform the
design of complimentary novel interventions.
In conclusion, REHAB-HF is a multi-center randomized control trial that will address key
evidence gaps by determining if a novel physical rehabilitation intervention will improve
physical function and reduce all-cause rehospitalizations following an ADHF hospitalization
in older, frail patients with multiple comorbidities and severe impairments in physical
function. The trial results could have a major impact on the management of older patients
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with ADHF by improving the morbidity, reduced quality-of-life, and high health care costs
associated with the nearly 1 million rehospitalizations annually in older HF patients.68
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Figure 1.

Approximate percent of exercise time in each physical function domain based on functional
level.
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REHAB-HF Inclusion and Exclusion Criteria
Inclusion Criteria
Patients eligible for the trial must meet the following criteria at randomization:
•

Age ≥ 60 years old

•

In the hospital setting >24 hours for the management of ADHF, defined as:
–

–

At least one symptom of HF which has worsened from baseline:
♦

Dyspnea at rest or with exertion

♦

Exertional fatigue

♦

Orthopnea

♦

Paroxysmal nocturnal dyspnea (PND)

At least two of the signs of HF
♦

Author Manuscript

–

Pulmonary congestion or edema on exam (rales) or by chest x-ray

♦

Elevated jugular venous pressure or central venous pressure ≥ 10 mm Hg

♦

Peripheral edema

♦

Wedge or left ventricular end diastolic pressure ≥15 mmHg

♦

Rapid weight gain (≥ 5 lbs.)

♦

Increased b-type natriuretic peptide (BNP) (≥100 pg/ml) or N-terminal prohormone BNP (≥220pg/ml)

Change in medical treatment specifically targeting HF defined as change in dose or initiation of or augmentation of at
least one of the following therapies
♦

Diuretics

♦

Vasodilators

♦

Inotropes (including digoxin if for HF)

♦

Other neurohormonal modulating agents, including angiotensin converting enzyme inhibitors, angiotensin
II receptor blockers, beta-blockers, aldosterone or direct renin inhibitors

Author Manuscript

•

Clinical stability to allow participation in study assessments and the intervention

•

Prior to admission, patient was independent with basic activities of daily living (ADLs) including the ability to ambulate
independently (with or without the use of an assistive device)

•

Able to walk 4 meters (with or without the use of an assistive device) at the time of enrollment

Exclusion Criteria
At the time of randomization, none of the following conditions may exist:
•

Acute myocardial infarction based on clinical diagnosis

•

Requiring care in an intensive care unit

•

Planned discharge other than to where the participant will live independently

•

Dementia that precludes ability to participate in rehabilitation and follow study protocols

•

Impairment from stroke, injury or other medical disorder that precludes participation in the intervention

•

Advanced chronic kidney disease (eGFR < 20 mL/min/1.73 m2) or dialysis

Author Manuscript

•

Prior cardiac transplantation or planned within the next 6 months

•

Expected use of continuous intravenous inotropic therapy after discharge

•

Ventricular assist device or anticipated within the next 6 months

•

Severe aortic valve stenosis

•

Already actively participating in facility-based cardiac rehabilitation
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Inclusion Criteria
Anticipated hospital discharge before baseline study measures could be completed
•
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Author Manuscript
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X
X
X

X
X

X
X
X
X
X
X
X

KCCQ

SF-12

EQ-5D-5L

GDS-15

MoCA

Clinical Events

Medications
Review
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X

Geriatric
conditions:
Falls
Urinary
incontinence
X

X

X

X

X

X

X

X

X

X

X

X

X

X

X
(6 months)

3.5, 4, 5, &
6 Months
(phone
call)

6MWT = Six Minute Walk Test; GDS = Geriatric Depression Scale; KCCQ = Kansas City Cardiomyopathy Questionnaire; MoCA = Montreal Cognitive Assessment; SF = Short Form; SPPB = Short
Physical Performance Battery; EQ-5D-5L = EuroQol 5-Dimension 5-Level

X

X

X

Medical
Resource Use

X

X

X

X

Biomarkers

X

X

X

X

X

X

SPPB

Frailty
Phenotype

X

X

6MWT

X

3 Months
(Visit)

1 Month
(Visit)

2 Months
(phone
call)
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Index
Hospitalization
(Baseline)
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Table 3
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Performance Levels for Strength, Balance, Mobility and Endurance

Strength: Rise from chair
without hand support
Balance: Standing
Endurance: Continuous
walking
Mobility: Gait speed

Level 1

Level 2

Level 3

Level 4

unable

at least once

5 times in > 15
but <60 seconds

5 times in ≤
15 seconds

unable with feet
together for 10
seconds

with feet together
for 10 seconds

unsupported and
reach forward 10
inches

on 1 leg for
10 seconds

< 2 minutes

≥ 2 but < 10
minutes

≥ 10 but
< 20 minutes

≥ 20 minutes

≤ 0.4 m/s

> 0.4 but ≤ 0.6 m/s

> 0.6 but ≤ 0.8 m/s

> 0.8 m/s
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Table 4
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Examples of Exercise Prescription by Performance Levels for each exercise domain: Strength, Balance,
Mobility and Endurance
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Exercise
Examples by
Domain

Level 1

Level 2

Level 3

Level 4

Strength
a) Sit to stand
b) Step-ups (front
and side)

On edge of chair
leaning forward and
pushing with hands
4 inch step*

On edge of chair
leaning forward with
arms reaching out
6 inch step*

In back of chair
with arms across
chest
8 inch step*

As in Level 3 at
faster pace or from
lower surface
10 inch step and/or
with resistance*

Balance
Stand and reach

Stand with feet
shoulder width
apart; reach forward
6 inches and hold.

Stand with feet
shoulder width
apart; reach
forward 10 inches
and hold.

Stand with feet
together; reach
forward 6 inches
(progressing to 10
inches) and hold

Semi-tandem
stance; reach
forward 6 inches
(progressing to 10
inches) and hold

Endurance:
Continuous
walking

Repeated brief
bouts for a total
duration of 10
minutes

Repeated brief
bouts for a total
duration of 20
minutes

Repeated bouts for
a total duration of
30 minutes

Continuous for 2030 minutes

Mobility
Gait training

Stop and start
abruptly

Brief accelerations
during walking

Quick change of
direction

Quick change of
direction while
engaged in activity
requiring cognitive
attention (e.g.
conversation,
questioning)

Frequency and duration: Outpatient 3x/week for approximately 60 minute sessions integrating all domains (goal 36 sessions). Inpatient: 30 minute
sessions daily until discharge with focus on domains to preserve functional mobility (when feasible; typically 0–2 sessions).
Intensity: RPE <12 initially; increasing to 13 (11–15) for endurance; 15–16 for strength. Balance and mobility not to exceed endurance RPE.
Mode: Exercises appropriate to a participant’s performance level in each domain (Table 3) are selected as illustrated in the examples above.
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Progression: As performance improves, participants advance to slightly more challenging exercises through structured, small increments.
Performance is assessed during one-on-one training sessions, including standardized re-assessment of functional performance in each domain
(Table 3) conducted every 2 weeks.

*

Performed with support of two hands, support of one hand, or no hand support.

Author Manuscript
Am Heart J. Author manuscript; available in PMC 2018 March 01.

